AR130892A1 - Inhibidores de mk2 y usos de los mismos - Google Patents
Inhibidores de mk2 y usos de los mismosInfo
- Publication number
- AR130892A1 AR130892A1 ARP230102880A ARP230102880A AR130892A1 AR 130892 A1 AR130892 A1 AR 130892A1 AR P230102880 A ARP230102880 A AR P230102880A AR P230102880 A ARP230102880 A AR P230102880A AR 130892 A1 AR130892 A1 AR 130892A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitors
- compositions
- formula
- methods
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención proporciona compuestos, composiciones de los mismos y métodos de uso de inhibidores de MK2 de la fórmula: (1).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263381195P | 2022-10-27 | 2022-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130892A1 true AR130892A1 (es) | 2025-01-29 |
Family
ID=90832108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102880A AR130892A1 (es) | 2022-10-27 | 2023-10-27 | Inhibidores de mk2 y usos de los mismos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240190890A1 (es) |
| EP (1) | EP4608401A2 (es) |
| KR (1) | KR20250094717A (es) |
| CN (1) | CN120390642A (es) |
| AR (1) | AR130892A1 (es) |
| TW (1) | TW202432106A (es) |
| WO (1) | WO2024092115A2 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014238443A1 (en) * | 2013-03-15 | 2015-07-30 | Celgene Car Llc | MK2 inhibitors and uses thereof |
| SI3193611T1 (sl) * | 2014-09-17 | 2021-08-31 | Celgene Car Llc | Inhibitorji MK2 in njihove uporabe |
| WO2016145234A2 (en) * | 2015-03-12 | 2016-09-15 | Moerae Matrix, Inc. | Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same |
| EP4363416A4 (en) * | 2021-06-30 | 2025-06-04 | Kymera Therapeutics, Inc. | MK2 DEGRADING AGENTS AND THEIR USES |
-
2023
- 2023-10-26 CN CN202380087972.6A patent/CN120390642A/zh active Pending
- 2023-10-26 US US18/495,004 patent/US20240190890A1/en active Pending
- 2023-10-26 KR KR1020257017260A patent/KR20250094717A/ko active Pending
- 2023-10-26 EP EP23883749.6A patent/EP4608401A2/en active Pending
- 2023-10-26 TW TW112141130A patent/TW202432106A/zh unknown
- 2023-10-26 WO PCT/US2023/077897 patent/WO2024092115A2/en not_active Ceased
- 2023-10-27 AR ARP230102880A patent/AR130892A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240190890A1 (en) | 2024-06-13 |
| KR20250094717A (ko) | 2025-06-25 |
| CN120390642A (zh) | 2025-07-29 |
| WO2024092115A3 (en) | 2024-07-04 |
| TW202432106A (zh) | 2024-08-16 |
| WO2024092115A2 (en) | 2024-05-02 |
| EP4608401A2 (en) | 2025-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003191A1 (es) | Inhibidores de tead y usos de los mismos | |
| CL2021003190A1 (es) | Inhibidores de tead y usos de los mismos | |
| MX2022001151A (es) | Inhibidores deuterados de la via mk2 y metodos de uso de los mismos. | |
| CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
| MX2022002877A (es) | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos. | |
| UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| MX2020001103A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| CO2023014770A2 (es) | Degradadores de cdk2 y sus usos | |
| ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
| UY29886A1 (es) | Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones | |
| ES2039269T3 (es) | Derivados de azolilmetil-ciclopropilo. | |
| PA8596901A1 (es) | Inhibidores de p38 y metodos de uso de ellos | |
| UY29176A1 (es) | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen, métodos para su preparación y sus usos. | |
| CL2022002402A1 (es) | Inhibidores del eif4e y sus usos | |
| UY29360A1 (es) | Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones. | |
| MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
| CO2023010023A2 (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| ZA202304734B (en) | Alpha protein kinase 1 inhibitors and methods of use | |
| BR112023015590A2 (pt) | Antagonistas de gpr84 e usos dos mesmos | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| MX2024013019A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| DOP2022000070A (es) | Inhibidor de diacilglicerol aciltransferasa 2 | |
| MX389581B (es) | Compuestos que contienen nitrogeno sustituido. | |
| CL2020003214A1 (es) | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5 | |
| MX2023009059A (es) | Antagonistas de gpr84 y usos de estos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |